Infectious Diseases Testing Products Segment tContribute Significantly tPoint of Care Diagnostics Market
According tour new research study on “Point of Care Diagnostics Market Forecast t2028 – COVID-19 Impact and Global Analysis – by Product, Prescription Mode, and End User,” the market is expected treach US$ 82,958.3 million by 2028 from US$ 36,000.4 million in 2021; it is estimated tgrow at a CAGR of 12.7% from 2021 t2028. The report highlights trends prevailing in the market, and the factors driving and hindering the market growth. The market growth is primarily attributed tincrease in prevalence of infectious diseases, product developments and launches, and rise in number of CLIA-waived POC tests. However, product recalls are expected thamper the market growth.
Point of care testing (POCT) is described as medical diagnostic testing at or near the point of care that is, at time and place of patient care. The purpose of POCT is tprovide immediate information tphysicians about the patient's condition. POCT is an important diagnostic tool used in various locations in the hospital such as the intensive care unit (ICU), the operating room (OR), and the emergency department (ED). Based on product, the point of care diagnostics market is segmented intglucose monitoring, infectious disease testing, cardiometabolic testing, pregnancy and fertility testing, coagulation testing, tumor/cancer marker testing, cholesterol testing, urinalysis testing, hematology testing, and other POC products. The infectious diseases segment is further subsegmented intHIV testing, influenza testing, sexually transmitted disease (STD) testing, hepatitis C testing, healthcare-associated infection (HAI) testing, tropical disease testing, respiratory infection testing, and other infectious disease testing. In 2020, the glucose monitoring segment held the largest share of the market. However, the infectious diseases segment is estimated tregister the highest CAGR of 14.1% during the forecast period.
The point of care diagnostics market is witnessing substantial growth amid the COVID-19 pandemic. Certain factors such as sudden rise in coronavirus infections and exponential growth in COVID-19 diagnostic kits played a prominent role in the growth of the point of care diagnostics market during the pandemic. In addition, the growing demand for rapid test kits for faster diagnosis at public places is alsestimated thave positive impact on the market growth.
F. HOFFMANN-LA ROCHE LTD.; Danaher; BIO-RAD LABORATORIES INC.; Abbott; Johnson and Johnson Services, Inc.; Siemens AG; BD; BioMerieux SA; Polymer Technology Systems, Inc. (PTS); and Nova Biomedical are among the leading companies operating in the point of care diagnostics market.
The report segments point of care diagnostics market as follows:
By Product
- Glucose Monitoring
- Infectious Disease Testing
- HIV Testing
- Influenza Testing
- Sexually Transmitted Disease (STD) Testing
- Hepatitis C Testing
- Healthcare-Associated Infection (HAI) Testing
- Tropical Disease Testing
- Respiratory Infection Testing
- Other Infectious Disease Testing
- Cardiometabolic Testing
- Pregnancy and Fertility Testing
- Coagulation Testing
- Tumor/Cancer Marker Testing
- Cholesterol Testing
- Urinalysis Testing
- Hematology Testing
- Other POC Products
By Prescription Mode
- Prescription-Based Testing
- OTC Testing
By End User
- Professional Diagnostic Centers
- Hospitals
- Clinical Laboratories
- Outpatient Healthcare
- Ambulatory Care Settings
- Home Care
- Research Laboratories
- Others
By Geography
- North America
- Europe
- France
- Germany
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific (APAC)
- China
- India
- Japan
- Australia
- South Korea
- Rest of APAC
- Middle East and Africa (MEA)
- Saudi Arabia
- UAE
- South Africa
- Rest of MEA
- South and Central America (SCAM)
Contact UsContact Person: Sameer JoshiPhone: +1-646-491-9876Email Id: sales@reportsweb.com
